India · Delayed Price · Currency is INR Emcure Pharmaceuticals Statistics
Total Valuation
NSE:EMCURE has a market cap or net worth of INR 442.79 billion. The enterprise value is 458.88 billion.
| Market Cap | 442.79B |
| Enterprise Value | 458.88B |
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Sep 4, 2026 |
Share Statistics
NSE:EMCURE has 189.68 million shares outstanding. The number of shares has increased by 0.17% in one year.
| Current Share Class | 189.68M |
| Shares Outstanding | 189.68M |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 70.34% |
| Owned by Institutions (%) | 13.88% |
| Float | 41.76M |
Valuation Ratios
The trailing PE ratio is 40.50 and the forward PE ratio is 30.19. NSE:EMCURE's PEG ratio is 1.23.
| PE Ratio | 40.50 |
| Forward PE | 30.19 |
| PS Ratio | 4.28 |
| PB Ratio | 8.19 |
| P/TBV Ratio | 10.23 |
| P/FCF Ratio | 49.05 |
| P/OCF Ratio | 31.96 |
| PEG Ratio | 1.23 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.52, with an EV/FCF ratio of 50.86.
| EV / Earnings | 41.51 |
| EV / Sales | 4.43 |
| EV / EBITDA | 22.52 |
| EV / EBIT | 28.39 |
| EV / FCF | 50.86 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.57 |
| Quick Ratio | 0.77 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 0.87 |
| Debt / FCF | 1.97 |
| Interest Coverage | 13.98 |
Financial Efficiency
Return on equity (ROE) is 21.37% and return on invested capital (ROIC) is 17.57%.
| Return on Equity (ROE) | 21.37% |
| Return on Assets (ROA) | 10.22% |
| Return on Invested Capital (ROIC) | 17.57% |
| Return on Capital Employed (ROCE) | 25.27% |
| Weighted Average Cost of Capital (WACC) | 4.25% |
| Revenue Per Employee | 14.80M |
| Profits Per Employee | 1.58M |
| Employee Count | 6,914 |
| Asset Turnover | 1.05 |
| Inventory Turnover | 1.78 |
Taxes
In the past 12 months, NSE:EMCURE has paid 4.02 billion in taxes.
| Income Tax | 4.02B |
| Effective Tax Rate | 26.88% |
Stock Price Statistics
The stock price has increased by +70.43% in the last 52 weeks. The beta is -0.00, so NSE:EMCURE's price volatility has been lower than the market average.
| Beta (5Y) | -0.00 |
| 52-Week Price Change | +70.43% |
| 50-Day Moving Average | 1,945.63 |
| 200-Day Moving Average | 1,751.70 |
| Relative Strength Index (RSI) | 75.88 |
| Average Volume (20 Days) | 282,290 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:EMCURE had revenue of INR 102.34 billion and earned 10.93 billion in profits. Earnings per share was 57.64.
| Revenue | 102.34B |
| Gross Profit | 59.63B |
| Operating Income | 15.98B |
| Pretax Income | 14.94B |
| Net Income | 10.93B |
| EBITDA | 19.63B |
| EBIT | 15.98B |
| Earnings Per Share (EPS) | 57.64 |
Balance Sheet
The company has 1.47 billion in cash and 17.57 billion in debt, with a net cash position of -16.09 billion or -84.85 per share.
| Cash & Cash Equivalents | 1.47B |
| Total Debt | 17.57B |
| Net Cash | -16.09B |
| Net Cash Per Share | -84.85 |
| Equity (Book Value) | 53.44B |
| Book Value Per Share | 281.68 |
| Working Capital | 21.89B |
Cash Flow
In the last 12 months, operating cash flow was 13.70 billion and capital expenditures -4.77 billion, giving a free cash flow of 8.92 billion.
| Operating Cash Flow | 13.70B |
| Capital Expenditures | -4.77B |
| Depreciation & Amortization | 3.64B |
| Net Borrowing | -389.50M |
| Free Cash Flow | 8.92B |
| FCF Per Share | 47.05 |
Margins
Gross margin is 58.26%, with operating and profit margins of 15.62% and 10.68%.
| Gross Margin | 58.26% |
| Operating Margin | 15.62% |
| Pretax Margin | 14.60% |
| Profit Margin | 10.68% |
| EBITDA Margin | 19.18% |
| EBIT Margin | 15.62% |
| FCF Margin | 8.72% |
Dividends & Yields
This stock pays an annual dividend of 3.60, which amounts to a dividend yield of 0.15%.
| Dividend Per Share | 3.60 |
| Dividend Yield | 0.15% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.25% |
| FCF Payout Ratio | 7.65% |
| Buyback Yield | -0.17% |
| Shareholder Yield | -0.01% |
| Earnings Yield | 2.47% |
| FCF Yield | 2.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for NSE:EMCURE is 2,422.50, which is 3.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 2,422.50 |
| Price Target Difference | 3.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 14.70% |
| EPS Growth Forecast (3Y) | 23.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |